Geron Corp (NASDAQ:GERN)

CAPS Rating: 3 out of 5

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

Recs

0
Player Avatar bddc4 (< 20) Submitted: 5/12/2011 12:14:28 PM : Outperform Start Price: $4.97 GERN Score: -69.78

stem cells are the future in medicine.

Featured Broker Partners


Advertisement